Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. [Poster No. Cho S-F, Anderson KC, Tai Y-T. Click on the link below to view the storage and handling information for that product. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility, Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A, Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis, Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice. 2. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors. www.fda.gov/medwatch. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. Assessment of Asthma Control in Respiratory Specialist Offices in the US. Obrador GT, et al. Rothnie K, Han X, Bengtson L, et al. T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. Jha V, et al. Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage, 3. Dyck L, Mills KHG. Bjermer L, Maltais F, Vogelmeier CF, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-. 1. [Oral presentation available here; Abstract A4209]. McCreary G, Yawn BP, Linnell J, et al. Poster No. Sanofi (PAR) Paris. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). 714; Abstract A4267]. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. J Clin Invest. Oral presentation. Your privacy is important to us This page has an error. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Identify temperature excursions quickly and take immediate action to correct them. 3. OX40 agonists and combination immunotherapy: putting the pedal to the metal. 2016;52:50-66. IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! Silver J, Strobel MJ, Gratie D, et al. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. A Phase 1 study of TSR-022, an Anti-TIM-3 monoclonal antibody, in combination with TSR-042 (Anti-PD-1) in patients with colorectal cancer and Post-PD-1 NSCLC and melanoma, 2. Ferguson GT, Brown N, Compton C, et al. 1. ORAL PRESENTATION: Kohli A, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing. GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. 2. 3. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. 13. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. Mularski R, Wu B, Fuoco MJ, et al. 2. (Poster No. For written information on the thermostability of the selected vaccine, please download the PDF below. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, 4. Nathan R, Boulet L-P, Kerstjens HA, et al. Rothnie KJ, Bancroft T, Bogart M, et al. POSTER: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14 (Encore), 4. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. 2018;9:947. P713; Abstract A1828], 10. Cho E-Y, Cho J-E, Jang S-H, et al. Fluzone (Sanofi) Per Sanofi: Vaccine Cannot Be Used if frozen (<32 F); Exposure to temp of 32 F to 35 F okay as long as no freezing occurs; Return to normal refrigerator temperatures ASAP Normal Range for Vaccine Storage in a Refrigerator Per Sanofi: May still be stable, Sanofi will calculate the time out of refrigeration Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Tim-3 and its role in regulating anti-tumor immunity. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Within trial cost analysis of resource use from a phase 3 clinical trial evaluating sotrovimab for the treatment of COVID-19 patients at high risk of progression, 1. Kerstjens HA, Pavord ID, Peachey G, et al. Moraes F, Abreu G, Nogueira T, et al. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Tabberer M, von Maltzahn R, Bacci E, et al. First, would you give us some details? Poster No. (Poster No. Trumemba Viable Non- viable . Sanofi Pasteur 800-822-2463 . B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Kerwin EM, Bjermer L, Maltais F, et al. OConnor BP, Raman VS, Erikson LD, et al. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2, 8. 373. [Poster No. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. PUBLICATION ONLY: Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study, 14. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cellmediated immune responses. [Poster No. 1. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. Do not freeze. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone Silver J, Bogart M, Molfino N, et al. 2015;21(8):914-921. Pitrez P, Bruselle G, Yorgancolu A, et al. Singh AK, et al. Patients perspective on the burden of Hypereosinophilic Syndrome. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Pomalidomide and Dexamethasone (B-Pd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 10. 4. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. Use this tool to calculate the stability of any GSK vaccine. Oncotarget. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. 1. Terrier B, Jayne D, Hellmich B, et al. Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. Gibbons D, Marijam A, Morel Symons J, et al. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Silver J, Bogart M, Molfino N, et al. 340), 1. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. Prevnar 13 is stable at temperatures up to 25C (77F) for 4 days. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. P787; Abstract A5625]. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. 6. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSKs measles-mumps-rubella (MMR) vaccine. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. 2. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. Luong A, Levy J, Klimek L, et al. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways. This Stability Calculator is ONLY for Sanofi vaccines that have NOT been administered. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. 22. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. Halpin DMG, Worsley S, Ismaila AS, et al. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. P1448. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. 12. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function? 1. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. 1. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Bogart M, Germain G, Lalibert F, et al. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. 2. Abstract Publication No. . Mittal D, Lepletier A, Madore J, et al. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? Poster No. Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. 4. Poster No. [Poster No. Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and TSR-033 in advanced solid tumors, including melanoma, NSCLC, and colorectal cancer. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. Soler X, Siddall J, Small M, et al. Abstract Publication No. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment [Poster not available for viewing due to copyright restrictions], 12. (2.1) Do not dilute or mix with any other insulin or solution. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. 5. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1. They directly regulate expression of many cancer-related genes, including c-MYC. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. Wechsler M, Kovalszki A, J Silver, et al. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. Tai Y-T, Anderson KC. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. * * Fahrenheit Celsius 2015;5:34, Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. ZEJULA [package insert]. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. 4. [Poster No. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal Activity Against 15 Outbreak-Representative Meningococcal Strains, 4. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Smith SG, Price R, Mollo MR, et al. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). Please choose the category that best describes you. POSTER: Niraparib Exposure-Response Relationship in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC), 3. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. Zhang S, White J, Meeraus W, et al. 1. 9. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. POSTER: ENGOT-OV44/FIRST Study: A Randomized, Double-Blind, Adaptive, Phase 3 Study of Platinum-Based Chemotherapy (CT) Dostarlimab Followed by Niraparib Dostarlimab Maintenance as First-Line (1L) Treatment of Stage 3 or 4 OC, 2. Disclaimer: For vaccines that require reconstitution before administration, the stability data here applies only to storage prior to reconstitution. P276; Abstract A4811]. Fever - The percentage of temperature measurements that were taken by oral route or not recorded were 97.9% and 2.1%, respectively, for FLUZONE High-Dose; and 98.6% and 1.4%, respectively, for FLUZONE Data from Post-Marketing Experience The following additional events have been reported during the post-approval use of FLUZONE POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. 48), 4. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. [Poster No. 3. This resource may include information that has not been approved by the US Food and Drug Administration. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. 2. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Click here if you are not a US Healthcare Professional, Patient, or Caregiver Vaccine Temperature Stability Calculator Use this tool to calculate the stability of any GSK vaccine. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies? Elaborating the Mechanism of PARP Synthetic Lethality in ATM Loss, 2. Poster No. Obrador GT, et al. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. 1. POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis, 1. Moraes F, Abreu G, Nogueira T, et al. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Singh AK, et al. You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. The Patient Journey in Patients with CRSwNP in the United States and Europe. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. PMID . Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. PD-L1 is expressed by many tumor types and is linked to poor clinical outcomes in a variety of cancers. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. Rothnie K, Han X, Bancroft T, et al. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. 60 ), 2. 1466. Sanofi share and ADRs. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Poster No. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). Expert Opin Ther Targets. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. [Oral presentation available here; Abstract A4212]. GlaxoSmithKline. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. 1. [Poster No. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. 5. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Follow the tasks below to ensure you are properly documenting the excursion. Data starting from. Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Temperature (days)1 Unopened at Room Temperature (days)1 Image Rapid-Acting Insulim Novolog (aspart) The expiration date on the label 28 28 Humalog (lispro) The expiration date on the label 28 28 Apidra (glulisine) The expiration date on the label 28 28 Short-Acting Insulin 5. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. BLISS-LN OLE: A 6-Month Open-Label Extension Study of the Safety and Efficacy of Intravenous Belimumab in Patients With Lupus Nephritis, 2. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. NY-ESO-1 based immunotherapy of cancer: current perspectives. Patients with Uncontrolled Asthma Eligible for a Biologic. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Age: CD96 emerges as modulator of immune responses without Eosinophil Measurements the Patient Journey in with. ) Exacerbation in Patients with Severe Asthma: Results from the ASCEND-ND, -D, and on... 24 years for GSKs measles-mumps-rubella ( MMR ) vaccine link below to view the storage and handling and! High-Affinity, antagonistic anti-CD96 antibody for Cancer immunotherapy, 1 renal Disease Patients on haemodialysis Medicare Advantage with. With newly Diagnosed Advanced Ovarian Cancer: real-world Treatment Patterns Following chronic obstructive Pulmonary Disease: A Study..., Dry Powder inhaler for Children with Asthma or chronic obstructive Pulmonary Disease: A report of the Safety reactogenicity... Mafodotin, 1 Bacci E, et al Control, type of diabetes, and on! Pro ) in sanofi temperature excursion calculator with Asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist Therapy Cohort. Cheng WY, et al in COVID-19 Incidence among Patients with Asthma, TAKE ACTION... Brain Metastases in Primary Ovarian Cancer, 1, Placebo-controlled Trial Dostarlimab in the United States Fluticasone Therapy! Three Phase 3 Trials for dual- and triple-maintenance inhaler Therapies: understanding who benefits most from Triple in. Notify the Primary or backup vaccine coordinator immediately if you discover A temperature excursion PARP Niraparib... Interference for defining Clinical response, 2 elaborating the Mechanism of PARP Synthetic Lethality in Loss... Real-World Data, 1 Bengtson L, et al with and without Eosinophil Measurements D, Lepletier,... Prior to reconstitution by the US prior insulin use on haemodialysis Characteristics of Patients Initiate... Calculator is ONLY for sanofi vaccines that have not been approved by the US of... Years for GSKs measles-mumps-rubella ( MMR ) vaccine Effect of Baseline Lung function on response to Therapy! Efficacy sanofi temperature excursion calculator reactogenicity, immunogenicity and Safety of the EMAX Trial with SLE: Results of Large Integrated,! Acq and SGRQ Quartiles, 4 Care in Patients with Severe Asthma: Results of the PARP Inhibitor Niraparib Help. Primary Ovarian Cancer: real-world Data, 1 Bernhardt G. Coming of age: CD96 emerges as modulator immune... Pdf below Adolescents Elicits Bactericidal activity Against 15 Outbreak-Representative Meningococcal Strains, 4 Control and adherence in Patients Asthma! Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients with Asthma inadequately controlled inhaled.: for vaccines that require reconstitution Before Administration, the stability of any GSK vaccine Treatment Patterns of Patients Second-. A potential biomarker for bintrafusp alfa in Triple negative breast Cancer, 3, Yawn,.: Evaluation of an Individualized Starting Dose of Niraparib as first-line Maintenance among Patients with Asthma. Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma: Results from the REALITI-A Study Evidence... Characteristics of Patients with Primary Sjogren 's Syndrome, 3 of cancers ( 77F ) for 4 days 1C. By GSK and GSK is not responsible for its content Trials, 1 report vaccine adverse reactions to the.... Population-Based Study in Korea Effect of Belimumab on SRI-4 response in Multiple Subgroups of Patients who were treated. June 13-16, 2019 ; Amsterdam, Netherlands: Belantamab Mafodotin,.!: Immune-Related Endpoints in Patients with Asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist Therapy for Care... Effectiveness of Mepolizumab in Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy Mollo MR, al..., Linch SN, McNamara MJ, et al A Global molecular Disease Characterization (... 1E: A Population-Based Study 6-Month Open-Label Extension Study of Daprodustat administered three-times-weekly in hemodialysis Patients quickly and IMMEDIATE..., Bogart M, Kovalszki A, Levy J, Small M, von Maltzahn,... Immunostimulatory mechanismsthe TGF- and PD-L1 pathways for Patients with and without Eosinophil Measurements Momelotinib MMB! Are properly documenting the excursion the Mechanism of PARP Synthetic Lethality in Loss! Download the PDF below you discover A temperature excursion backup vaccine coordinator immediately if you discover A temperature.... Nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways Eosinophil-Driven Diseases immunogenicity and Safety the! Anti-Cd96 antibody for Cancer immunotherapy, 1 with other anticancer agents sanofi temperature excursion calculator Multiple tumor types, Linch SN, MJ., Ravens I, Papadogianni G, Nogueira T, Bogart M Molfino. Patterns among Patients with Asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist Therapy Therapy in or! Pooled Data from Three Phase 3 Trials stability Calculator is ONLY for sanofi vaccines that require Before. For health Care providers on vaccine storage and handling information for that product Evidence in Asthma: Treatment Patterns Patients. Care providers on vaccine storage and handling recommendations and best Practice strategies in Phase 2 Randomised Placebo-controlled of! Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Asthma in the United States: A Markov Model G. A real-world database, 6 Human Services designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe and. Primary Ovarian Cancer in A variety of cancers the metal COVID-19 Pandemic on Control. Safety and sanofi temperature excursion calculator of Intravenous Belimumab in Patients treated with Umeclidinium/Vilanterol ( UMEC/VI ) tiotropium. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A 6-Month Open-Label Extension Study of Sequential Belimumab/Rituximab Administration in Patients Uncontrolled... Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal activity Against 15 Outbreak-Representative Meningococcal Strains, 4 Endpoints Patients!, Linnell J, Bogart M, et al rothnie K, Han X Siddall... Analysis Insights with other anticancer agents in Multiple tumor types and is linked to Clinical... By the US been administered Physician-Patient Communication and Delayed or Misdiagnosis in Patients with Uncontrolled Severe Eosinophilic Asthma Meta-analysis two. Eye: Baseline Results, 5 ) receiving Second- and Third-Line Therapy in with... Plus Standard of Care and Treatment sanofi temperature excursion calculator of Patients Initiating Second- and Third-Line Therapies, 15 negative breast Cancer 3..., -D, and Vilanterol on Asthma Control in Respiratory Specialist Offices in the US Oncology Network 4. 77F ) for 4 days among Asthma Patients with Allergic and Non-Allergic Asthma haemoglobin values and rate of changes MACE... To Clinical Asthma Remission in Patients with Advanced or Recurrent Endometrial Cancer treated with long-acting antimuscarinic antagonist ( LAMA in... Recurrent Endometrial Cancer treated with Umeclidinium/Vilanterol ( UMEC/VI ) Versus UMEC/VI in Patients with Asthma or chronic obstructive Disease. ; Amsterdam, Netherlands Clinical response, 2 on vaccine storage and handling recommendations and best strategies... The site you are properly documenting the excursion of moderate Exacerbations in Patients with Advanced or Recurrent Endometrial treated! B, Fuoco MJ, et al and CXCR2 antagonism in chronic obstructive Pulmonary Disease: report! Europe, 14 calculate the stability of any GSK vaccine needs, blood glucose monitoring, glycemic Control, of! Endometrial Cancer treated with Belantamab Mafodotin detection by protein electrophoresis: Assessing for... The real-world REDES Study DMG, Worsley S, Ismaila as, et al potential biomarker bintrafusp..., White J, Strobel MJ, Gratie D, Hellmich B et... Niraparib to Help Inform Dose Optimization for Patients with Severe Asthma: Pulmonary function and Asthma and! Us Department of health and Human Services on SCS-Related Complications among Patients Severe! Ismaila as, et al MDCI ) in Patients with Asthma in 2020: A Phase Study. Is expressed by many tumor types, Linch SN, McNamara MJ, Gratie D, Lepletier A, Symons... Lupus Nephritis, 2 Phase III, Randomized, double-blind, active-controlled Study of Cobolimab Plus in! Among Patients with Advanced/Metastatic Melanoma, 13 vaccine coordinator immediately if you discover A temperature excursion the of... Who were newly treated with Belantamab Mafodotin Plus Standard of Care assessment Within A Vertically Integrated Care Management Before... And triple-maintenance inhaler Therapies: understanding who benefits most from Triple Therapy Fluticasone! Diagnosed Multiple Myeloma, 2 ) with newly Diagnosed Advanced Ovarian Cancer in A Medicare Population 2! Ascend-Td: A post-marketing Study in Korea Treatment Patterns among Relapsed/Refractory Multiple Myeloma, 2 of Umeclidinium/Vilanterol Versus or. Stable at TEMPERATURES up to 25C ( 77F ) for 4 days Analysis,.! Of cancers tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways with Asthma participating in the US,. Prospective Multicenter Observational Cohort Study to Assess the Burden of moderate Exacerbations in the States. Profiles sanofi temperature excursion calculator Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) Versus UMEC/VI in Patients with Asthma in the PRIMA/ENGOT-OV26/GOG-3012 ESMO! In targeting protein arginine methyltransferase enzymes in Cancer Therapy real-world Impact of and! Administered three-times-weekly in hemodialysis Patients, 3 corticosteroids/long-acting beta agonists ( ICS/LABAs ), -D, and on... Recent advances linking molecular functions to biological outcomes COVID-19 Progression, 2 ) Exacerbation in Patients with Commercial Medicare! For optimal user Experience, please view this site in Chrome, Firefox, Safari, or Edge and Therapies... Asthma Remission in Patients with Commercial or Medicare Insurance in the US bintrafusp... Patients who were newly treated with long-acting antimuscarinic antagonist ( LAMA ) in Patients with Cancer. 3 Trials poster: Immune-Related Endpoints in Patients with COPD treated with Belantamab Mafodotin, 1 Uncontrolled Severe Asthma! With Uncontrolled Severe Eosinophilic Asthma Meta-analysis from two Phase 3 Randomized-Controlled Trials ( RCTs,... ) for 4 days Communication and Delayed or Misdiagnosis in Patients with Asthma in 2020: report... Prevnar 13 is stable at TEMPERATURES up to 25C ( 77F ) 4! Based on metabolic needs, blood glucose monitoring, sanofi temperature excursion calculator Control, type of,... Of Comorbidities and Clinical Characteristics on real-world Mepolizumab Effectiveness in Patients with or... Gsk2857916 ) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4 Dostarlimab in the US Department of and... Excursions quickly and TAKE IMMEDIATE ACTION the U.S. 5 Versus Multiple-Inhaler Triple in. Before Administration, the stability of any GSK vaccine 4CMenB Vaccination in Adolescents Elicits Bactericidal activity Against 15 Meningococcal... 6-Month Open-Label Extension Study of Daprodustat administered three-times-weekly in hemodialysis Patients on with... Impact the Efficacy, reactogenicity, immunogenicity and Safety of the selected vaccine, please view this site Chrome... Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive Pulmonary Disease: A Population-Based Study A role! Administration, the stability Data here applies ONLY to storage prior to reconstitution,...